Provided by Tiger Trade Technology Pte. Ltd.

Entrada Therapeutics, Inc.

10.32
+0.16001.57%
Post-market: 10.320.00000.00%17:01 EST
Volume:102.42K
Turnover:1.06M
Market Cap:394.42M
PE:-4.10
High:10.40
Open:10.20
Low:10.15
Close:10.16
52wk High:21.79
52wk Low:4.93
Shares:38.22M
Float Shares:21.58M
Volume Ratio:0.54
T/O Rate:0.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.5151
EPS(LYR):1.76
ROE:-27.11%
ROA:-15.71%
PB:1.16
PE(LYR):5.87

Loading ...

Entrada Therapeutics Grants Stock Options and RSUs to New Employees Under 2025 Inducement Plan

Reuters
·
Dec 05

Entrada Therapeutics CFO Kory James Wentworth Reports Disposal of Common Shares

Reuters
·
Nov 25

Major Stock Sell-Offs at Entrada Therapeutics Inc!

TIPRANKS
·
Nov 19

Director and 10% Owner Kush Parmar Reports Disposal of Entrada Therapeutics Inc. Common Shares

Reuters
·
Nov 19

5AM Ventures V, L.P. Reports Sale of Entrada Therapeutics Inc. Common Shares

Reuters
·
Nov 19

Baker Bros. Advisors LP Acquires Common Shares of Entrada Therapeutics Inc

Reuters
·
Nov 13

Promising Advancements and Strategic Positioning Drive Buy Rating for Entrada Therapeutics Inc.

TIPRANKS
·
Nov 07

BRIEF-Entrada Therapeutics may issue up to $400 million in securities - SEC filing

Reuters
·
Nov 06

Entrada Therapeutics files $400M mixed securities shelf

TIPRANKS
·
Nov 06

Entrada Therapeutics Inc - May Issue up to $400 Mln in Securities - SEC Filing

THOMSON REUTERS
·
Nov 06

Entrada Therapeutics Unveils Pipeline Progress and Clinical Milestones for Neuromuscular Disease Therapies

Reuters
·
Nov 06

Entrada Therapeutics Q3 net loss widens to $44.1 mln

Reuters
·
Nov 06

Entrada Therapeutics Q3 EPS $(1.06) Misses $(0.95) Estimate, Sales $1.614M Miss $13.702M Estimate

Benzinga
·
Nov 06

Entrada Therapeutics, Inc. Q3 EPS USD -1.06

THOMSON REUTERS
·
Nov 06

Entrada Therapeutics: Expected Cash Runway Extended Into Q3 2027 With $327 Mln in Cash, Cash Equivalents & Marketable Securities as of Sept 30

THOMSON REUTERS
·
Nov 06

Entrada Therapeutics: on Track to Report Elevate-44-201 Data From First Patient Cohort in Q2 2026

THOMSON REUTERS
·
Nov 06

Entrada Therapeutics Inc expected to post a loss of 94 cents a share - Earnings Preview

Reuters
·
Oct 31

Entrada Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire
·
Oct 28

William Blair Sticks to Their Buy Rating for Entrada Therapeutics Inc (TRDA)

TIPRANKS
·
Oct 24

Entrada Therapeutics initiated with Early-Stage Biotech at Goldman Sachs

TIPRANKS
·
Sep 17